2021
Antibacterial Resistance Leadership Group 2.0: Back to Business
Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL, Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler VG. Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases 2021, 73: 730-739. PMID: 33588438, PMCID: PMC8366825, DOI: 10.1093/cid/ciab141.Peer-Reviewed Original Research
2014
Antibacterial Resistance Leadership Group: Open for Business
Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG. Antibacterial Resistance Leadership Group: Open for Business. Clinical Infectious Diseases 2014, 58: 1571-1576. PMID: 24610430, PMCID: PMC4017892, DOI: 10.1093/cid/ciu132.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupAntibacterial resistanceClinical research agendaPublic health threatClinical research opportunitiesInfection preventionClinical studiesAntimicrobial stewardshipClinical research proposalsInfectious diseasesClinical researchHealth threatNational InstituteInfectionMedical practiceHigh priority areasNegative bacteriaPositive bacteriaAllergyDiseasePrevention